Cold Plasma Diabetic Foot Ulcer Clinical Trial Published

https://www.woundsinternational.com/journals/issue/667/article-details/efficacy-non-thermal-gas-plasma-treatment-diabetic-foot-ulcers-stalled-subclinical-biofilm-related-wound-infection

Congratulations to Dr Cornelia Wiegand for her published clinical trial paper, “The efficacy of non-thermal gas plasma in the treatment of diabetic foot ulcers stalled by subclinical, biofilm-related wound infection”. This clinical trial paper features the use of our SteriPlas Cold Plasma medical device for the treatment of chronic DFUs infected with biofilm.

 

The parameters of this study were set much higher than a normal study, with there being a much higher standard of care given (3x per week) vs a typical outpatient setting of 1x weekly.

 

We wanted to show that even when chronic diabetic foot ulcers are subjected to more frequent outpatient visits with biopsies and swabs included (something not often collected during standard outpatient visits), SteriPlas Cold Plasma still prevails as the successful treatment method due to its physical mode of action and ability to kill all types of bacteria protected within biofilm.

 


Presentation at the DFSG 2022

We're so excited for exhibiting at the Diabetic Foot Study Group (DFSG) conference next week. Please be sure to visit us at booth no.11 where we will based during the conference. We welcome you to see our SteriPlas Cold Plasma medical device live in action.

We're also excited to announce that the Diabetes Team at Kettering General Hospital NHS Foundation Trust will have a poster presentation illustrating the strong antibacterial efficacy and healing qualities of the Adtec SteriPlas for diabetic foot ulcers.

The poster, "DGH EXPERIENCE OF USING COLD PLASMA MEDICAL DEVICE AS AN ADJUNCT THERAPY TO ANTIMICROBIALS IN TREATING CHRONIC NON HEALING INFECTED DIABETIC FOOT ULCERS" will be presented by Jemma Cruickshank on Saturday 17th September, 13:25 - 14:25.

See you all soon!


Antimicrobial (antibiotic) Resistance – the drugs won’t work !

Antimicrobial resistance (AMR) poses a significant global threat of far-reaching proportions. It is estimated that drug resistant infections contribute to nearly 5 million deaths every year and predicted to increase to over 10 million deaths every year.  WHO has declared that AMR is one of the top 10 global public health threats facing humanity.

(The worldwide total deaths from COVID is now just over 6 million and we all know how frightening it was before the vaccine was developed)

 

AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”. Without effective antimicrobials, the success of modern medicine in treating infections, including during major surgery and cancer chemotherapy, would be at increased risk. Chronic infections if left untreated could result in tissue damage, amputation, longer stays in hospitals, surgical interventions, or increased possibility of mortality. Patients who are infected with drug-resistant infections are more likely to develop complications and are up to three times more likely to die from the infection. Non-healing wounds in particular, are characterised by complex and mixed bacterial populations, often involving antibiotic-resistant bacteria as well as phenotypically tolerant bacteria in biofilm form. The biofilm factor is clearly of considerable clinical importance: it protects bacteria from antimicrobial agents leading to persistent and difficult to treat chronic infections, and it exacerbates the spread of antibiotic resistance. Surgical Site Infections are also linked to anti-microbial resistance.

 

SteriPlas cold plasma technology kills bacteria by a physical mode of action and bacteria are therefore unlikely to develop primary or secondary resistance, which we have documented from our clinical studies. SteriPlas cold plasma also kills antibiotic resistant bacteria (e.g. MRSA) and kills bacteria encased in biofilm which are typically up to 1000 times more resistant to antibiotics. SteriPlas has proven clinical efficacy in treating wound infections,  diabetic foot infections and surgical site infections in all clinical studies, all with the bonus of no side effects reported. 

 

SteriPlas cold plasma can be used to treat topical infections reserving antibiotics for severe systemic infections.

 

References

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext

https://www.worldometers.info/coronavirus/

https://www.who.int/health-topics/antimicrobial-resistance

https://healthfirsteurope.eu/wp-content/uploads/2020/11/A3A4-48pp-Booklet-Spreads-1.pdf

Bowler, P., Murphy, C. & Wolcott, R. Biofilm exacerbates antibiotic resistance: Is this a current oversight in antimicrobial stewardship?. Antimicrob Resist Infect Control 9, 162 (2020).


Diabetic Foot Study Group Conference

Are you excited as we are?

Looking forward to resuming exhibition season at the Diabetic Foot Study Group conference in Slovakia.

We'll be exhibiting between 16-18 Sept with our Adtec SteriPlas on demonstration ready to show you just how quick and effective it is to use and combat antibiotic resistant bacteria within diabetic foot ulcers.


Next week welcomes the start of the exhibition season

Find us next week at the Society for Cardiothoracic Surgeons in Belfast from 8-10 May. We'll be at booth 18 ready to welcome you and introduce the benefits of #coldplasma in cardiothoracic #infection conditions.

 

From 10-13 May, we will also be exhibiting at the Malvern Diabetic Foot Conference looking forward to seeing regular faces from this prestigious conference.

 

We will have our Adtec SteriPlas medical device on our booths, ready to give you a live demonstration of how effective cold plasma is at killing bacteria protected within biofilm.

 


The Safety and Reliability of our Cold Plasma

Is our cold plasma safe?

 

Yes!

 

As you can see from the photo, our Adtec technician demonstrates touching the cold plasma jet.

 

An extensive list of practical tests and experiments were conducted during our first stage, pre clinical studies and ongoing post-market studies. This allowed us to carefully develop a cold plasma medical device that could bring all the antibacterial benefits but at the same time remain painless and contact-free so that it could be well tolerated in patient treatments. We were after all the first company worldwide to introduce cold plasma treatment on wounds demonstrated in our clinical trials.

 

As cold plasma can be generated through a variety of ways, they are also dependent on the plasma source design and surrounding environment. The components of plasma include reactive oxygen and nitrogen species and UV that need to be controlled to ensure they are within safe levels for medical use. Some plasma devices may also deliver fluctuating inconsistent cold plasma output as they are sensitive to changes in humidity and temperature in the treatment room. This may often result in undesirable side effects.

 

Because the Adtec SteriPlas is a low energy, microwave-powered, cold atmospheric argon plasma medical device this means its safety remains the main priority in line with delivering repeatable and successful results. It is also the reason why we are proud to state our medical device has NO side effects associated to it.


Our patented 6 electrode Cold Plasma Torch

The Adtec SteriPlas features a patented 6 electrode cold plasma torch. It’s proven efficacy for the destruction of all forms of bacteria including multi-resistant bugs makes it an alternative to antibiotic therapy for the treatment of wounds, surgical site infections and medical dermatology skin conditions. This is due to the unique physical mode of action delivered with our cold plasma as opposed to the chemical mode of action demonstrated with antibiotics. Broader studies have shown that antimicrobial resistance is unlikely to be generated with cold plasma treatment because of this.

 

A huge collection of our peer reviewed publications documents the clinical efficacy and safety of our medical device across a broad range of conditions including diabetic foot ulcers, left ventricular assist device (LVAD) infections, deep sternal wound infections, actinic keratoses and acne.

 

To learn more about our medical device or to obtain one in your clinic practice, please contact us at info@adtecplasma.com

 


Adtec Healthcare's Conference and Exhibition attendance dates for 2022

As we look forward to a promising year ahead, please find the dates of our conference and exhibition participation for 2022:

Society for Cardiothoracic Surgery (SCTS) Annual Meeting – 8-10 May 2022

Malvern Diabetic Foot Conference – 11-13 May 2022

European Wound Management Association (EWMA) – 23-25 May 2022

Diabetic Foot Study Group (DFSG) – 16-18 September 2022

 

We hope to see you at either of these conferences and as always, we will have our flagship medical device, the Adtec SteriPlas, on demonstration ready for you to test and to see all the benefits linked to our cold plasma strengths for wounds, surgical site infections and medical dermatology.

 

 

 

 


Quick results achieved with the Adtec SteriPlas

How often do LVAD patients with infection need treatment with the Adtec SteriPlas?

 

We recommend a minimum treatment of twice per week. This applies to both outpatients in day clinics and inpatients who have been admitted into the wards.

 

The treatment time itself is as quick as 3 minutes. During these short minutes, the components of cold plasma quickly bombard the cellular structure of bacteria to create micropores which allows access to the microbial DNA for total destruction. This applies to all forms of bacteria regardless of their resistance profile or if they are protected within biofilm.

 

How quick have patients with LVAD infections healed?

 

Our clinical evidence has shown patients have healed in as quick of two weeks of treatment. These are patients who have failed previous therapeutic attempts with conventional treatment methods.


Promising, consistent and reliable results achieved with the Adtec SteriPlas

 

Whilst Left ventricular assist devices (LVADs) have become essential mechanical pumps for patients who have had end stage heart failures, they are also prone to infections especially with the presence of biofilm that complicates treatment options. Cardiologists often rely on conventional antibiotic therapy but with rising antimicrobial resistance rates, they sometimes offer little to no help in achieving stabilisation.

The strong properties of the Adtec SteriPlas cold plasma has been proven to offer complete stabilisation of the LVAD system by destroying all forms of multi-resistant bacteria present, even if they are protected within biofilm. This is due to the unique cold plasma properties that can travel through the gaps around and down the driveline to reach the site of biofilm. This area would normally have been difficult to treat with conventional therapies such as antimicrobial dressings as they are hard to reach, but the Adtec SteriPlas has shown to travel to these sites with ease due to its remarkable antibacterial gaseous properties.

 

To learn more about our strong collection of clinical evidence, please contact us at info@adtecplasma.com to learn more